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Abstract
Nuclear receptors retinoic X receptor a (RXRa) and peroxisome proliferator activated receptor c (PPARc) function potently in
metabolic diseases, and are both important targets for anti-diabetic drugs. Coactivation of RXRa and PPARc is believed to
synergize their effects on glucose and lipid metabolism. Here we identify the natural product magnolol as a dual agonist
targeting both RXRa and PPARc. Magnolol was previously reported to enhance adipocyte differentiation and glucose
uptake, ameliorate blood glucose level and prevent development of diabetic nephropathy. Although magnolol can bind
and activate both of these two nuclear receptors, the transactivation assays indicate that magnolol exhibits biased agonism
on the transcription of PPAR-response element (PPRE) mediated by RXRa:PPARc heterodimer, instead of RXR-response
element (RXRE) mediated by RXRa:RXRa homodimer. To further elucidate the molecular basis for magnolol agonism, we
determine both the co-crystal structures of RXRa and PPARc ligand-binding domains (LBDs) with magnolol. Structural
analyses reveal that magnolol adopts its two 5-allyl-2-hydroxyphenyl moieties occupying the acidic and hydrophobic
cavities of RXRa L-shaped ligand-binding pocket, respectively. While, two magnolol molecules cooperatively accommodate
into PPARc Y-shaped ligand-binding pocket. Based on these two complex structures, the key interactions for magnolol
activating RXRa and PPARc are determined. As the first report on the dual agonist targeting RXRa and PPARc with receptor-
ligand complex structures, our results are thus expected to help inspect the potential pharmacological mechanism for
magnolol functions, and supply useful hits for nuclear receptor multi-target ligand design.
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Introduction
Nuclear receptors are ligand-regulated transcription factors,
involving multiple signalling pathways, among which RXRa and
PPARc are in the central positions. RXRa plays its role in diverse
physiological processes, including cell development, apoptosis, and
homeostasis [1,2]. And it predominantly expresses in liver, kidney,
epidermis and intestine [3]. RXRa agonists have been found to
exhibit glucose-lowing, insulin-sensitizing, as well as anti-obesity
effects [4]. For example, LGD1069, which is approved for the
treatment of cutaneous T-cell lymphoma, also shows decreased
fasting plasma glucose and insulin in ob/ob mice [5]. While another
RXRa agonist LG100268 exhibits its efficiency in reducing fasting
plasma glucose and improving insulin resistance [6]. Thus, RXRa
agonists have great potentials for the treatment of metabolic
diseases.
PPARc distributes in adipose tissue, regulating adipocyte
differentiation, lipid storage, inflammation, hypertension, and
atherosclerosis [7]. It has favourable effects on glucose uptake,
lipid metabolism and energy expenditure. Moreover, its activation
promotes adipogenesis and insulin sensitivity [8]. PPARc agonists
are reported to exhibit a variety of pharmacological potentials in
anti-hyperglycemia, anti-hyperinsulinemia, and lowering triglyc-
erides in adipose, muscle and liver [9]. Thiazolidinediones (TZDs)
targeting PPARc, such as Rosiglitazone and Pioglitazone, have
been approved to improve insulin sensitivity. Considering the
undesirable side effects of TZDs [9], a new type of chemical
compounds with therapeutic properties but different from TZDs
are in urgent needs.
Once activated by their agonists, RXRa and PPARc translocate
into the nucleus forming RXRa:RXRa homodimer or RXRa:P-
PARc heterodimer, which subsequently binds to RXRE or PPRE
to initial their target genes transcription, respectively [10].
Recently, there are increasing numbers of reports on the
synergistic effects of RXRa and PPARc agonists. As indicated,
coactivation of RXRa and PPARc exhibits enhanced efficiencies
in the metabolism of glucose and lipid [11], as well as the
inhibition of cancer cell migration and invasiveness [12].
Combined treatment with RXRa and PPARc agonists also inhibit
nitric oxide and tumor necrosis factor-alpha production in rat
Kupffer cells [13], and suppress proliferation of immortalized
endometrial stromal cells [14]. All these facts have thus addressed
the pharmacological significances of RXRa and PPARc coactiva-
tion by their agonists. However, the dual agonist that binds and
activates both RXRa and PPARc has not been reported by far.
In the current work, we screen our house in-lab library of
natural products for RXRa and PPARc agonists. Interestingly, we
find that magnolol is a dual agonist of both RXRa and PPARc.
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e28253Magnolol (5,59-diallyl-2,29-dihydroxybiphenyl, Figure 1A) is one
of the main constituents from the stem bark of Magnolia officinalis,
which is used in the traditional Chinese medicine to cure cough,
diarrhea and allergic rhinitis [15]. Magnolia bark was also
suggested to be effective in combating metabolic syndrome [16].
Treatment with magnolol decreased fasting blood glucose and
plasma insulin levels, and prevented the pathological complica-
tions in type 2 diabetic rats [17]. Remarkably, magnolol was
reported to enhance adipocyte differentiation and glucose uptake
in 3T3-L1 adipocyte cells [18] and prevent the development of
diabetic nephropathy [17]. Moreover, the high glucose-induced
TGFb1 and fibronectin expressions were inhibited by magnolol via
ERK/MAPK/Akt signalling pathway in human retinal pigment
epithelial cells under diabetic conditions [19], while the anti-
oxidative and hepatoprotective effects of magnolol were shown on
liver damage in rats [20].
Although magnolol can bind and activate both RXRa and
PPARc, the transactivation results shows biased agonism of
magnolol to induce the transcription of PPRE mediated by
RXRa:PPARc heterodimer, instead of RXRE mediated by
RXRa:RXRa homodimer. To reveal the molecular basis for
magnolol function, we determine the crystal structures of both
RXRaLBD-magnolol and PPARcLBD-magnolol. Based on these
two complex structures, we find that magnolol adopts surprising
binding modes on RXRa and PPARc with key interactions for
magnolol agonism determined. Therefore, our results are expected
to not only shed light on the potential pharmacological application
for magnolol, but also supply useful hits for multi-target drug
design based on the nuclear receptors.
Results and Discussion
In the discovery of new ligands from the lab in-house natural
products library against RXRa and PPARc, we construct a
screening platform based on in-cell mammalian one hybrid assays.
Among the natural products with the activities to activate either
RXRa or PPARc, magnolol unexpectedly shows its agonistic
functions on both of these two nuclear receptors, with EC50 values
of 10.4 mM and 17.7 mM, respectively (Figure 1B and C).
Additionally, the magnolol-induced RXRa and PPARc activa-
tions can be suppressed by the known RXRa and PPARc
antagonists HX531 and GW9662, respectively (Figure 1B and
C), implying that magnolol takes its effects by targeting both of
these two nuclear receptors. We further perform surface plasmon
resonance (SPR) technology based experiments to detect the
physical binding of magnolol to the purified RXRaLBD and
PPARcLBD. As indicated in Figure 1D and E, magnolol dose-
dependently binds to RXRaLBD and PPARcLBD with KD values
of 45.7 mM and 1.67 mM, respectively.
As nuclear receptors, RXRa and PPARc need to recruit their
coactivators to initiate the transcription of target genes [4]. Thus
we further investigate whether magnolol can enhance these two
nuclear receptors binding to the common coactivator steroid
receptor coactivator-1 (SRC1) using SPR based technology. As
indicated in Figure 1F, magnolol can increase RXRaLBD-SRC1
interactions in a dose-dependent manner. However, this natural
product exhibits no effect on SRC1 recruitment to PPARcLBD
(Figure 1G). Considering there are many other coactivators for
PPARc function [7], magnolol may probably take its effect by
recruiting other coactivator instead of SRC1 for PPARc involved
transcription.
In activation of the downstream genes transcription, RXRa and
PPARc have to form RXRa:RXRa homodimer and RXRa:P-
PARc heterodimer binding to their response elements. Thus we
further evaluate the effects of magnolol on the activities of
RXRa:RXRa homodimer and RXRa:PPARc heterodimer using
transactivation analyses on their response elements RXRE and
PPRE. As indicated in Figure 2A and B, magnolol induces the
transcription of PPRE in a dose-dependent manner. However, this
compound exhibits no activity on RXRE transcription. Moreover,
the magnolol-effect on PPRE transcription can be suppressed by
both RXRa and PPARc antagonists HX531 and GW9662,
respectively (Figure 2B), which is in good accordance to our in-
cell mammalian one hybrid assays (Figure 1B and C). It thus
indicates that magnolol binding to both RXRa and PPARc is
required to activate PPRE transcription. Additionally, magnolol
exhibits lower activities in their lower concentrations, compared to
PPARc agonist Rosiglitazone (Figure 2C). However, magnolol
surprisingly shows equal activities to Rosiglitazone in their high
concentrations, indicating magnolol is a PPARc full agonist
(Figure 2C). In conclusion, we identify magnolol from the natural
product library functioning as a dual agonist of both RXRa and
PPARc, with the biased transcriptional activity on PPRE instead
of RXRE.
As indicated in the previously reported crystal structures of
RXRa ligand-binding domain complex with agonists, the essential
activation function-2 (AF-2) motif in RXRa exhibits significant
conformational changes. AF-2 motif overturns itself to cover the
ligand-binding pocket upon agonist binding, thus exposing the
surface for recruiting the coactivator SRC1 and initializing the
transcription of target genes [21,22,23]. The typical chemical
structure of RXRa agonist consists of the acidic and hydrophobic
moieties to adapt the L-shaped ligand-binding pocket of RXRa
[5,6]. Different from previously reported RXRa agonists,
magnolol possesses two identical 5-allyl-2-hydroxyphenyl moieties.
Thus we wonder how magnolol functions as an agonist of RXRa.
To reveal the molecular basis for magnolol binding and activating
RXRa, we determine the crystal structure of RXRaLBD-
magnolol complex with SRC1 coactivator peptide. Magnolol-
bound RXRaLBD exhibits a dimeric packing of RXRa. The
electron density around magnolol is shown in Figure 3A.
Magnolol binds into the hydrophobic ligand-binding pocket, and
induces conserved conformational changes of AF-2 motif for
SRC1 coactivator peptide recruitment. Magnolol is found to adapt
itself to an L-shaped conformation, with two 5-allyl-2-hydro-
xyphenyl moieties occupying each side of the L-shaped pocket,
respectively. The typical RXRa agonists always form a hydrogen
bond with Arg316 in the C-terminus of helix 5 [5,6]. However,
magnolol uses one hydroxyl group to form a hydrogen bond with
Asn306 in the N-terminus of helix 5 (Figure 3B). Such an
interaction induces an overturning of Asn306, compared with the
known agonist 9-cis-retinoic acid-bound RXRaLBD structure
(Figure 3B). Moreover, helix 3 is observed to bend towards the
ligand-binding pocket from its position in apo RXRaLBD
structure, which is consistent with the known agonist-bound
RXRaLBD structures [5,6]. Therefore, from our determined
crystal structure of RXRaLBD-magnolol-SRC1, the agonist
magnolol employs a distinct binding mode for RXRa activation
by interacting with Asn306 in the N-terminus of helix 5, instead of
Arg316 in the C-terminus of helix 5. And magnolol adapts its two
5-allyl-2-hydroxyphenyl moieties occupying the hydrophobic and
acidic sides of the pocket, respectively.
Different from RXRa with the L-shaped ligand-binding pocket,
PPARc uses a much larger Y-shaped pocket for ligand-binding
[24]. And PPARc ligand-binding pocket can be divided into two
sub-pockets, AF-2 sub-pocket and b-sheet sub-pocket [24]. PPARc
agonists are categorized as full and partial agonists, depending on
their activities in the cell-based reporter assays [25]. It is suggested
Magnolol as RXRa and PPARc Dual Agonist
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full agonists always occupy both AF-2 and b-sheet sub-pockets to
activate PPARc [26]. Magnolol is determined to be a full agonist
of PPARc in the current work (Figure 2C). Thus we wonder how
magnolol binds such a Y-shaped pocket for PPARc activation. In
our determined crystal structure of PPARcLBD-magnolol, the
electron density map around magnolol is shown in Figure 3C.
Interestingly, two magnolol molecules are found in PPARc ligand-
binding pocket, one in AF-2 sub-pocket and the other in b-sheet
sub-pocket. The hydroxyl group of magnolol in AF-2 sub-pocket
forms a hydrogen bond with Ser289 in helix 3, as well as water-
mediated hydrogen bonds with Tyr473 in AF-2 motif (Figure 3D).
Direct interactions between agonist and AF-2 motif are believed to
play a crucial role in the conformational changes of PPARc AF-2
motif, and surface formation for coactivator recruitment [26]. On
the other side, the hydroxyl group of magnolol in b-sheet sub-
pocket interacts with Ser342 in b-sheet with a hydrogen bond
(Figure 3D). Moreover, there is also a water-mediated hydrogen
bond with magnolol in b-sheet sub-pocket to further stabilize the
ligand binding (Figure 3D). Our findings have thus revealed an
unexpected binding mode of magnolol on PPARc, with two
identical chemical compounds binding two different sub-pockets,
which probably lead for new PPARc agonists design.
To evaluate the degree of cooperativity of the two magnolol
molecules binding to PPARc, Hill coefficient is determined. The
value of approximately 2 indicates that magnolol binding is
positively cooperative, and both the binding sites can bind
magnolol simultaneously. Thus two magnolol molecules cooper-
atively induce PPARc activation by interacting with both AF-2
motif and b-sheet, respectively. Furthermore, the fact that two
magnolol molecules cooperatively bind to PPARc also explains the
reason why magnolol exhibits lower activities on PPRE transcrip-
tion, compared to PPARc agonist Rosiglitazone (Figure 2C).
Although magnolol and Rosiglitazone are both PPARc full
agonists, their transactivation curves indicate their different
mechanisms (Figure 2C). Only one molecule of Rosiglitazone is
necessary for PPARc activation, while two magnolol molecules are
required to bind PPARc. Considering that the magnolol-effect on
PPRE transcription can also be suppressed by RXRa antagonist
HX531, and HX531 can inhibit RXRa agonist 9cRA activity on
PPRE, it thus suggests that magnolol binding to RXRa is also
necessary for PPRE transcription. Therefore, totally three
magnolol molecules are required for PPRE transcription, with
one molecule binding to RXRa and two molecules binding to
PPARc.
Magnolol was once characterized as a PPARc agonist with the
computer aided modelling [27]. However, our co-crystal structure
of PPARcLBD-magnolol reveals a distinct ligand binding mode.
As indicated in Figure 3D, magnolol in AF-2 sub-pocket is found
to form not only a hydrogen bond with Ser289 in helix 3, but also
water-mediated hydrogen bonds with Tyr473 in AF-2 motif. On
the other side, in b-sheet sub-pocket of PPARc, magnolol interacts
with Ser342 in b-sheet (Figure 3D), instead of Gly284 that was
determined by the computer aided modelling. Moreover, we also
find a water-mediated hydrogen bond with magnolol in b-sheet
sub-pocket to further stabilize the ligand binding (Figure 3D).
Considering that the water-mediated interactions within
PPARcLBD-magnolol is still delicate to be determined by the
computer based modelling, our co-crystal structure is expected to
supply further insights into the future computer based modelling.
Honokiol, an analogue of magnolol, shares some certain
biological properties with magnolol [28]. And honokiol was
reported to have anti-angiogenic, anti-inflammatory and antitu-
mor functions, but the mechanisms of honokiol actions are still
elusive. Here we find that magnolol targets both RXRaLBD and
PPARcLBD, thus how honokiol interacts with these two nuclear
receptors will be of potentially important and interesting.
Moreover, knowledge of mechanisms of magnolol and honokiol
actions may assist novel synthetic analogues development in the
future.
From the RXRaLBD-magnolol and PPARcLBD-magnolol
structures, it is suggested that the hydroxyl groups of magnolol
play essential roles in the receptor-ligand interactions. In
RXRaLBD-magnolol structure, the hydroxyl group of magnolol
contacts with Asn306 in helix 5 of RXRa. While, in PPARcLBD-
magnolol structure, the hydroxyl groups from the two bound
ligands interact with Ser342 in b-sheet, Tyr473 in AF-2 motif, and
Ser289 in helix 3 of PPARc, respectively. Additionally, magnolol
adopts surprising binding modes on these two nuclear receptors.
Although magnolol is big enough to accommodate mostly the L-
shaped RXRa ligand-binding pocket, two magnolol molecules
have to cooperatively occupy the much larger Y-shaped PPARc
ligand-binding pocket. Furthermore, the single bond connecting
the two 5-allyl-2-hydroxyphenyl moieties of magnolol endows this
chemical compound flexibility to fit the different pocket sizes of
RXRa and PPARc. As shown in Figure 4A, magnolol molecules
exhibit three different conformations when it binds to RXRa and
PPARc. Figure 4B and C show the key secondary structures of
RXRa and PPARc, with which magnolol makes direct interac-
tions. Our findings are in good accordance with that the homo-/
heterodimeric interface and coactivator binding surface of RXRa
and PPARc are critical for both of these two nuclear receptors
activation. And all of these secondary structures of RXRa and
PPARc are conserved in the agonist binding and interactions.
Considering the large differences between RXRa L-shaped pocket
and PPARc Y-shaped pocket, future dual agonist design may focus
on PPARc sub-pockets, since each PPARc sub-pocket has a
similar size to the whole pocket of RXRa. The agonist which can
accommodate to RXRa ligand-binding pocket and the two
PPARc sub-pockets with preferred activities will probably have
potentials to activate both of these two nuclear receptors.
Materials and Methods
Luciferase assays
Mammalian one hybrid and transactivation experiments were
performed using luciferase assays in HEK293T (human embry-
onic kidney) cells (obtained from ATCC). Transient transfection
was conducted using Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s guideline. For the mammalian one hybrid
tests for RXRa or PPARc, UAS-TK-Luc reporter plasmid
was co-transfected with GAL4DBD-RXRaLBD or GAL4DBD-
PPARcLBD. For the transactivation assays of RXRE or PPRE,
pGL3-RXRE-Luc was co-transfected with pcDNA3.1-RXRa,o r
Figure 1. Magnolol as a dual agonist of RXRa and PPARc. (A) Chemical structure of magnolol. (B–C) Magnolol dose-dependently activated the
transcription of GAL4DBD-RXRaLBD (B) and GAL4DBD-PPARcLBD (C) in HEK-293T cells, which could be suppressed by RXRa antagonist HX531 and
PPARc antagonist GW9662, respectively. RXRa agonist 9-cis-retinoic acid (9cRA) and PPARc agonist Rosiglitazone were used as positive controls. (D–
E) Magnolol dose-dependently bound to RXRaLBD (D) and PPARcLBD (E) in SPR technology based assays. (F–G) Magnolol dose-dependently
enhanced SRC1 recruitment to RXRaLBD (F), instead of PPARcLBD (G) in SPR technology based assays.
doi:10.1371/journal.pone.0028253.g001
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and pcDNA3.1-PPARc. Cells were incubated with varied
concentrations of compounds for 24 h. The known RXRa agonist
9-cis-retinoic acid (9cRA), RXRa antagonist HX531, PPARc
agonist Rosiglitazone, and PPARc antagonist GW9662 were used
as controls. All compounds were purchased from Sigma, dissolved
in DMSO, and prepared to different concentrations. Luciferase
activities were then measured using Dual Luciferase Assay System
kit (Promega).
Figure 2. Magnolol as a biased agonist on PPRE transcription.
(A–B) Magnolol could not activate the transcription of RXRE mediated
by RXRa:RXRa homodimer (A), while activating the transcription of
PPRE mediated by RXRa:PPARc heterodimer in a dose-dependent
manner (B). RXRa agonist 9cRA, RXRa antagonist HX531, PPARc agonist
Rosiglitazone, and PPARc antagonist GW9662 were used as controls. (C)
Activating curves of magnolol and Rosiglitazone on PPRE transcription
indicated that magnolol was a PPARc full agonist, although magnolol
exhibited lower activities in their lower concentrations.
doi:10.1371/journal.pone.0028253.g002
Figure 3. Crystal structures of RXRaLBD-magnolol-SRC1 and
PPARcLBD-magnolol. (A) Electron density of magnolol bound into
RXRa ligand-binding pocket in stereo view (contoured at 1.0s level). (B)
Comparison of receptor-ligand interactions between 9cRA-bound and
magnolol-bound RXRaLBDs. 9cRA (in blue sticks) formed hydrogen
bonds with Arg316 (in magenta sticks) in the C-terminus of helix 5 (in
magenta ribbon), while magnolol (in yellow sticks) formed hydrogen
bonds with Asn306 (in cyan sticks) in the N-terminus of helix 5. Density
map around Asn306 was shown in the right to indicate its
conformational changes. All other hydrophobic residues involving
9cRA (in magenta lines) or magnolol interactions were the same (shown
in cyan lines). (C) Electron density map of magnolol bound into PPARc
ligand-binding pocket in stereo view (contoured at 1.0s level). (D) The
two magnolol molecules formed hydrogen bonds with Ser342 in b-
sheet, Tyr473 in AF-2 motif, and Ser289 in helix 3 of PPARc, as well as
water-mediated hydrogen bonds.
doi:10.1371/journal.pone.0028253.g003
Magnolol as RXRa and PPARc Dual Agonist
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The coding sequence of human RXRaLBD (residues 221–458)
was cloned to the vector pET15b, and E. coli strain BL21 (DE3)
was used for protein expression. The culture was induced with
0.5 mM IPTG and incubated at 25uC for 6 hours. His-tagged
RXRaLBD was purified with Ni-NTA resin (Qiagen) and the tag
was then removed by Thrombin (Novagen). The protein was
further purified with Superdex 200 (Amersham Pharmacia
Biotech).
The coding sequence of human PPARcLBD (residues 204–477)
was cloned to the vector pGEX6P-1. GST-PPARcLBD was
expressed with 0.2 mM IPTG at 18uC for 6 hours. GST-tag was
removed by PreScission protease (GE Healthcare). The protein
was further purified with Superdex 200 (Amersham Pharmacia
Biotech).
The SRC-1 coactivator peptide was commercially synthesized
with the sequence KHKILHRLLQDSS.
Surface plasmon resonance (SPR) technology based
assays
Binding affinities of magnolol towards purified RXRaLBD and
PPARcLBD were analyzed using Biacore 3000 instrument (GE
Healthcare). Proteins were covalently immobilized to CM5 chip
using a standard amine-coupling procedure in 10 mM sodium
acetate buffer (pH 4.2). The chip was equilibrated with a
continuous flow of running buffer (10 mM HEPES, pH 7.4,
150 mM NaCl, 3 mM EDTA, 0.005% (v/v) surfactant P20) for
2 hours. Subsequently, magnolol in a gradient of concentrations
were injected into the channels at a flow rate of 20 mL/min for 60
seconds, followed by disassociation for 120 seconds. For the
coactivator SRC1 recruitment assays, biotin-labelled SRC1 was
immobilized to SA chip. Different concentrations of magnolol
were incubated with 5 mM RXRaLBD or PPARcLBD for 1 hour,
and then injected to the channel at a flow rate of 20 mL/min for
60 s, followed by disassociation for 120 s.
Crystallization
All crystallization experiments were performed by hanging-drop
method at 20uC. RXRaLBD was mixed with SRC-1 coactivator
Figure 4. Key interactions for magnolol function on RXRa and
PPARc. (A) Magnolol exhibited three different conformations upon
binding into RXRa and PPARc ligand-binding pockets. Magnolol in
RXRa ligand-binding pocket was shown in yellow, while the two
magnolol molecules in PPARc ligand-binding pocket were shown in
green and cyan, respectively. (B–C) Secondary structures with which
magnolol interacted were shown in both RXRa (B) and PPARc (C)
ligand-binding pockets. The functions of these secondary structures in
the coactivator recruitment, homo-/heterodimerization and DNA-
binding domain (DBD) interactions were indicated.
doi:10.1371/journal.pone.0028253.g004
Table 1. Data collection and refinement statistics.
RXRaLBD-magnolol-SRC1 PPARcLBD-magnolol
Data collection
Space group P21 21 21 P43 21 2
Cell dimensions
a, b, c (A ˚) 65.95, 65.83, 110.29 66.04, 66.04, 155.26
a, b, c (u) 90, 90, 90 90, 90, 90
Resolution (A ˚) 32.922.8 (2.8522.80)
[a] 40.022.0 (2.0722.00)
Rsym or Rmerge 0.056 (0.381) 0.053 (0.398)
I/sI 11.8 (2.7) 51.8 (7.2)
Completeness (%) 98.8 (99.7) 94.2 (90.7)
Redundancy 3.6 (3.6) 5.9 (6.3)
Refinement
Resolution (A ˚) 32.922.8 40.022.0
No. reflections 11 863 20 400
Rwork/Rfree 0.249/0.292 0.188/0.213
No. atoms 3 678 2 194
B-factors 47.1 41.0
R.m.s. deviations
Bond lengths (A ˚) 0.008 0.006
Bond angles (u) 1.103 0.968
Ramachandran plot (%)
Most favored regions 95.5 98.0
Allowed regions 4.5 2.0
[a]Values in parenthesis are for highest resolution shell.
doi:10.1371/journal.pone.0028253.t001
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condition of 100 mM Tris, pH 7.5, 20% PEG3350. For the
PPARcLBD-magnolol complex, the ratio of PPARcLBD:magno-
lol was 1:5. Crystals grew in the condition of 4 M sodium formate.
Data collection and structure determination
Diffraction data was collected at BL17U of Shanghai Synchro-
tron Radiation Facility in China, and integrated with HKL2000
[29]. Phasing and refinement were carried out with Refmac5 [30].
Model building was manually performed with COOT [31]. The
statistics of the data collection and structure refinement were
summarized in Table 1. Atomic coordinates and structure factors
of RXRaLBD-magnolol-SRC1 and PPARcLBD-magnolol have
been deposited to Protein Data Bank under accession codes 3R5M
and 3R5N.
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